UPCC 26124 A Phase 2 Study of Alisertib in Combination with Endocrine Therapy in Patients with HR+, HER2-Negative Recurrent or Metastatic Breast Cancer
Enrolling By Invitation
99 years or below
All
Phase
N/A
1 Location
Brief description of study
This is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Updated on
13 Nov 2024.
Study ID: 856940
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
